{"id":935129,"date":"2026-02-09T07:21:04","date_gmt":"2026-02-09T12:21:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/"},"modified":"2026-02-09T07:21:04","modified_gmt":"2026-02-09T12:21:04","slug":"beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/","title":{"rendered":"BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360\u00b0 Conference"},"content":{"rendered":"
\n

FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) — BeyondSpring Inc.<\/strong><\/a> (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies,\u00a0today announced\u00a0that the Company will participate in the Immuno-Oncology 360\u00b0 (IO360\u00b0) Conference 2026<\/a>, held February 10-12, 2026 in Boston, MA.<\/p>\n

Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1\/PD-LD blockade and highlight Plinabulin\u2019s unique mechanism of action and clinical development strategy.<\/p>\n

\n Presentation Details:<\/strong>
\n
Title: Overcoming PD-1\/L1 Resistance: Translational Insights with Plinabulin
Track Number: 1. Translational Science & Biomarkers \u2013 Expanding Therapeutic Horizons
Date: Wednesday, February 11, 2026
Time: 4:55PM to 5:10PM ET
Location: Sheraton Boston Hotel, Track 1, Grand Ballroom<\/p>\n

Following the presentation, the slides will also be available on the \u201cPosters and Presentations\u201d page of the Company\u2019s website.<\/p>\n

\n About BeyondSpring<\/strong>
\n
\n BeyondSpring<\/a> (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and other indications. Plinabulin\u2019s novel mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors resistant to checkpoint inhibitors. Learn more at https:\/\/beyondspringpharma.com<\/u><\/a>.<\/p>\n

\n Investor Contact: <\/strong>
\n IR@beyondspringpharma.com<\/a>
\n
\n Media Contact: <\/strong>
\n PR@beyondspringpharma.com<\/a>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies,\u00a0today announced\u00a0that the Company will participate in the Immuno-Oncology 360\u00b0 (IO360\u00b0) Conference 2026, held February 10-12, 2026 in Boston, MA. Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1\/PD-LD blockade and highlight Plinabulin\u2019s unique mechanism of action and clinical development strategy. Presentation Details: Title: Overcoming PD-1\/L1 Resistance: Translational Insights with PlinabulinTrack Number: 1. Translational Science & Biomarkers \u2013 Expanding Therapeutic HorizonsDate: Wednesday, February 11, 2026Time: 4:55PM to 5:10PM ETLocation: Sheraton Boston Hotel, Track 1, Grand Ballroom Following the presentation, the slides will also be available on … <\/p>\n

Continue reading “BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360\u00b0 Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-935129","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBeyondSpring to Participate at the 12th Annual Immuno-Oncology 360\u00b0 Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360\u00b0 Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies,\u00a0today announced\u00a0that the Company will participate in the Immuno-Oncology 360\u00b0 (IO360\u00b0) Conference 2026, held February 10-12, 2026 in Boston, MA. Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1\/PD-LD blockade and highlight Plinabulin\u2019s unique mechanism of action and clinical development strategy. Presentation Details: Title: Overcoming PD-1\/L1 Resistance: Translational Insights with PlinabulinTrack Number: 1. Translational Science & Biomarkers \u2013 Expanding Therapeutic HorizonsDate: Wednesday, February 11, 2026Time: 4:55PM to 5:10PM ETLocation: Sheraton Boston Hotel, Track 1, Grand Ballroom Following the presentation, the slides will also be available on … Continue reading "BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360\u00b0 Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-09T12:21:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MTA2NyM3NDE1Nzc5IzIwODA4ODQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360\u00b0 Conference\",\"datePublished\":\"2026-02-09T12:21:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\\\/\"},\"wordCount\":216,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MTA2NyM3NDE1Nzc5IzIwODA4ODQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\\\/\",\"name\":\"BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360\u00b0 Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MTA2NyM3NDE1Nzc5IzIwODA4ODQ=\",\"datePublished\":\"2026-02-09T12:21:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MTA2NyM3NDE1Nzc5IzIwODA4ODQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MTA2NyM3NDE1Nzc5IzIwODA4ODQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360\u00b0 Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360\u00b0 Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/","og_locale":"en_US","og_type":"article","og_title":"BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360\u00b0 Conference - Market Newsdesk","og_description":"FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies,\u00a0today announced\u00a0that the Company will participate in the Immuno-Oncology 360\u00b0 (IO360\u00b0) Conference 2026, held February 10-12, 2026 in Boston, MA. Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1\/PD-LD blockade and highlight Plinabulin\u2019s unique mechanism of action and clinical development strategy. Presentation Details: Title: Overcoming PD-1\/L1 Resistance: Translational Insights with PlinabulinTrack Number: 1. Translational Science & Biomarkers \u2013 Expanding Therapeutic HorizonsDate: Wednesday, February 11, 2026Time: 4:55PM to 5:10PM ETLocation: Sheraton Boston Hotel, Track 1, Grand Ballroom Following the presentation, the slides will also be available on … Continue reading \"BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360\u00b0 Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-09T12:21:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MTA2NyM3NDE1Nzc5IzIwODA4ODQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360\u00b0 Conference","datePublished":"2026-02-09T12:21:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/"},"wordCount":216,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MTA2NyM3NDE1Nzc5IzIwODA4ODQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/","name":"BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360\u00b0 Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MTA2NyM3NDE1Nzc5IzIwODA4ODQ=","datePublished":"2026-02-09T12:21:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MTA2NyM3NDE1Nzc5IzIwODA4ODQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MTA2NyM3NDE1Nzc5IzIwODA4ODQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beyondspring-to-participate-at-the-12th-annual-immuno-oncology-360-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360\u00b0 Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=935129"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935129\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=935129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=935129"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=935129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}